<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Bipolar major depression in adults: General principles of treatment</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Bipolar major depression in adults: General principles of treatment</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Bipolar major depression in adults: General principles of treatment</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">William V Bobo, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard C Shelton, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Keck, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David Solomon, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 19, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H672917682"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Bipolar disorder is marked by episodes of mania  (<a class="graphic graphic_table graphicRef91106" href="/d/graphic/91106.html" rel="external">table 1</a>) and hypomania  (<a class="graphic graphic_table graphicRef91107" href="/d/graphic/91107.html" rel="external">table 2</a>) and nearly always includes episodes of major depression  (<a class="graphic graphic_table graphicRef91398" href="/d/graphic/91398.html" rel="external">table 3</a>) [<a href="#rid1">1</a>]. Observational studies consistently show that depressive episodes predominate the clinical course of bipolar disorder [<a href="#rid2">2,3</a>]. Compared with manic and hypomanic episodes, bipolar depressive episodes and residual bipolar depressive symptoms account for a greater proportion of long-term morbidity, impaired functioning, and risk of suicide [<a href="#rid4">4,5</a>].</p><p>As a result, improved treatment of bipolar major depression is a patient priority. In an internet based survey from 11 countries, which asked patients with bipolar disorder (n = 1300) which aspects of care they would most like to see improved, better treatment of depression was endorsed by the largest number (&gt;40 percent) [<a href="#rid6">6</a>]. The second and third leading aspects of care that patients would most like to see improved were avoiding weight gain and preventing relapse of depressive episodes.</p><p>This topic reviews the general principles of treating bipolar major depression. Other topics discuss choosing treatment for adults with bipolar major depression, the efficacy and adverse effects of antidepressants and second generation antipsychotics for bipolar major depression in adults, investigational approaches to treating bipolar major depression in adults, choosing pharmacotherapy for adults with acute mania and hypomania, choosing maintenance treatment for adults, and choosing pharmacotherapy for pediatric bipolar major depression:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/15267.html" rel="external">"Bipolar major depression in adults: Choosing treatment"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/14655.html" rel="external">"Bipolar major depression in adults: Efficacy and adverse effects of antidepressants"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/16693.html" rel="external">"Bipolar major depression in adults: Efficacy and adverse effects of second-generation antipsychotics"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/115481.html" rel="external">"Bipolar major depression in adults: Investigational and nonstandard approaches to treatment"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/679.html" rel="external">"Bipolar mania and hypomania in adults: Choosing pharmacotherapy"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/680.html" rel="external">"Bipolar disorder in adults: Choosing maintenance treatment"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/99164.html" rel="external">"Pediatric bipolar major depression: Choosing treatment"</a>.)</p><p></p><p class="headingAnchor" id="H1957138767"><span class="h1">DEFINITION OF BIPOLAR DISORDER</span><span class="headingEndMark"> — </span>Bipolar disorder is a mood disorder that is characterized by periods of pathologic mood elevation (mania or hypomania) [<a href="#rid1">1</a>]. Patients with bipolar I disorder experience manic episodes  (<a class="graphic graphic_table graphicRef91106" href="/d/graphic/91106.html" rel="external">table 1</a>) and nearly always experience both hypomanic episodes  (<a class="graphic graphic_table graphicRef91107" href="/d/graphic/91107.html" rel="external">table 2</a>) and major depressive episodes  (<a class="graphic graphic_table graphicRef91398" href="/d/graphic/91398.html" rel="external">table 3</a>). Bipolar II disorder is characterized by at least one episode of hypomania  (<a class="graphic graphic_table graphicRef91107" href="/d/graphic/91107.html" rel="external">table 2</a>) and one or more major depressive episodes. In addition, psychotic features such as delusions and hallucinations frequently accompany bipolar depressive episodes, particularly in patients with bipolar I disorder [<a href="#rid7">7</a>].</p><p>Additional information about the clinical features and diagnosis of bipolar disorder, including bipolar major depression, is discussed separately. (See  <a class="medical medical_review" href="/d/html/14642.html" rel="external">"Bipolar disorder in adults: Clinical features"</a> and  <a class="medical medical_review" href="/d/html/86602.html" rel="external">"Bipolar disorder in adults: Assessment and diagnosis"</a>.)</p><p class="headingAnchor" id="H3519330921"><span class="h1">GENERAL PRINCIPLES</span></p><p class="headingAnchor" id="H3600586294"><span class="h2">Initial assessment</span><span class="headingEndMark"> — </span>Treatment of acute bipolar depressive episodes begins with a psychiatric and general medical history, mental status and physical examination, and focused laboratory and imaging studies as clinically indicated. Clinicians should assess current and past:</p><p class="bulletIndent1"><span class="glyph">●</span>Depressive symptoms and episodes  (<a class="graphic graphic_table graphicRef91398" href="/d/graphic/91398.html" rel="external">table 3</a>), including suicidal ideation and behavior</p><p class="bulletIndent1"><span class="glyph">●</span>Manic and hypomanic symptoms and episodes  (<a class="graphic graphic_table graphicRef91106" href="/d/graphic/91106.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef91107" href="/d/graphic/91107.html" rel="external">table 2</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Psychotic features such as delusions and/or hallucinations</p><p class="bulletIndent1"><span class="glyph">●</span>Substance abuse</p><p class="bulletIndent1"><span class="glyph">●</span>Treatment responses, including treatment-limiting adverse effects</p><p class="bulletIndent1"><span class="glyph">●</span>Patient preferences regarding treatment</p><p></p><p>Establishing a clear history of mania or hypomania meeting full diagnostic criteria is essential. Additional information about assessing patients for bipolar disorder is discussed separately. (See  <a class="medical medical_review" href="/d/html/86602.html" rel="external">"Bipolar disorder in adults: Assessment and diagnosis", section on 'Assessment'</a>.)</p><p class="headingAnchor" id="H611255908"><span class="h2">Goals</span><span class="headingEndMark"> — </span>The goals of acute treatment for bipolar depressive episodes is remission, defined as resolution of mood symptoms or improvement to the point that few symptoms of only mild intensity persist, and restored functioning [<a href="#rid8">8,9</a>]. However, remission can require several weeks or longer to occur; thus, a reasonable interim goal is response [<a href="#rid8">8,9</a>], defined as stabilization of the patient’s safety with clinically significant reduction in the number and severity of mood symptoms. Response includes resolution of suicidal ideation and psychotic features, when present. In addition, improvement in depressive symptoms should occur without precipitating treatment-emergent manic/hypomanic episodes or rapid cycling. In many studies that use rating scales to monitor response to treatment, response is defined as reduction of baseline symptoms ≥50 percent.</p><p class="headingAnchor" id="H777447613"><span class="h2">Setting</span><span class="headingEndMark"> — </span>Hospitalization may be required for the safety and stabilization of patients with severe bipolar depression accompanied by [<a href="#rid10">10</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Suicidal ideation with a plan and intent to kill oneself. (See  <a class="medical medical_review" href="/d/html/1708.html" rel="external">"Suicidal ideation and behavior in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Delusions or hallucinations that threaten the patient’s safety, such as command auditory hallucinations involving suicide. (See  <a class="medical medical_review" href="/d/html/17193.html" rel="external">"Psychosis in adults: Epidemiology, clinical manifestations, and diagnostic evaluation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Severe agitation. (See  <a class="medical medical_review" href="/d/html/291.html" rel="external">"Assessment and emergency management of the acutely agitated or violent adult"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Loss of functioning such that patients can no longer adequately care for themselves – As an example, patients may become dehydrated and malnourished due to refusal of liquids and food.</p><p></p><p>Patients with acute but moderate bipolar depression (such as those with fleeting suicidal ideation without suicidal intent or plan) can be treated in a partial hospitalization or intensive outpatient treatment program. Otherwise, most patients with bipolar depression can be managed as outpatients.</p><p class="headingAnchor" id="H2748906596"><span class="h2">Pharmacotherapy</span><span class="headingEndMark"> — </span>Choosing a specific medication regimen for acute episodes of bipolar I or II major depression is discussed separately. (See  <a class="medical medical_review" href="/d/html/15267.html" rel="external">"Bipolar major depression in adults: Choosing treatment"</a>.)</p><p>In selecting pharmacotherapy for patients with bipolar major depression, clinicians should understand that they are likely selecting a maintenance regimen as well, because medications that successfully resolve acute bipolar episodes are generally continued [<a href="#rid11">11,12</a>]. Maintenance treatment of bipolar disorder is discussed separately. (See  <a class="medical medical_review" href="/d/html/680.html" rel="external">"Bipolar disorder in adults: Choosing maintenance treatment"</a>.)</p><p>For patients with bipolar major depression who receive a second-generation antipsychotic as monotherapy, efficacy is often comparable for low doses and high doses, whereas discontinuation of treatment due to adverse effects may occur less often with low doses. As an example, a meta-analysis of four randomized trials (n &gt;1600 patients) compared fixed doses of <a class="drug drug_general" data-topicid="9570" href="/d/drug information/9570.html" rel="external">quetiapine</a> 300 mg/day with quetiapine 600 mg/day and found that symptomatic improvement, response (reduction of baseline symptoms ≥50 percent), and remission were each comparable for the two groups [<a href="#rid13">13</a>]. However, discontinuation of treatment due to adverse effects occurred less often with quetiapine 300 mg/day.</p><p>Nearly all of the high quality evidence that guides choosing a medication regimen consists of randomized trials that compared an active drug with placebo. Few head-to-head trials have compared different active drugs.</p><p>If patients respond poorly to a medication regimen that includes multiple drugs, we change one medication at a time.</p><p class="headingAnchor" id="H1660497968"><span class="h2">Duration of an adequate drug trial</span><span class="headingEndMark"> — </span>Based upon literature reviews [<a href="#rid14">14</a>] and multiple randomized trials [<a href="#rid15">15</a>], the duration of an adequate medication trial for patients with bipolar I or II major depression is usually six to eight weeks. Nearly all of the studies were conducted with outpatients.</p><p>However, in clinically urgent situations, such as inpatient hospitalization, it is typically not feasible to wait six to eight weeks to determine if a drug trial has sufficiently relieved symptoms. For these patients, if there is minimal improvement (eg, reduction of baseline symptoms &lt;20 percent) within the first few weeks (eg, two to three) of treatment with a specific medication, it may be acceptable to decide that response is unlikely to occur [<a href="#rid16">16,17</a>].</p><p>Using absence of early improvement to predict nonresponse is supported by a study of four randomized trials in which an active medication regimen was superior to placebo in bipolar I or II major depression (n &gt; 2000 patients) [<a href="#rid18">18</a>]. The active drugs consisted of <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a>, <a class="drug drug_general" data-topicid="9716" href="/d/drug information/9716.html" rel="external">olanzapine</a> plus <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a>, or <a class="drug drug_general" data-topicid="9570" href="/d/drug information/9570.html" rel="external">quetiapine</a>; the trials lasted seven or eight weeks; early improvement was defined as reduction of baseline symptoms ≥20 percent at week 2, and response was defined as reduction of baseline symptoms ≥50 percent. The analyses pooled the negative predictive values, which represented the probability that patients would not respond at the end of the study if they had not demonstrated early improvement. The pooled negative predictive value was high (74 percent) and the false positive rate was low (14 percent); these results were interpreted to mean that absence of early improvement was a highly reliable predictor of subsequent nonresponse. By contrast, the presence of early improvement did not reliably predict eventual response.</p><p class="headingAnchor" id="H1285622046"><span class="h2">Monitoring</span><span class="headingEndMark"> — </span>We recommend that clinicians monitor depressive symptoms, treatment response and adverse effects, and adherence to treatment at each visit [<a href="#rid16">16,19</a>]. Assessment frequency depends upon the severity of depressive symptoms, treatment setting, suicide risk, presence of psychotic features and comorbid psychopathology, and functional impairment. Hospitalized patients are assessed at least daily, and symptoms of suicidality or psychosis may necessitate constant monitoring. Outpatients who have responded well to treatment can be followed less frequently (typically every one to three weeks, depending upon residual symptom severity) until they achieve remission. Once remission is achieved and adequate medication tolerability and adherence are established, office visits can be scheduled less frequently (eg, every one to six months), depending upon factors such as prior course of illness, including the duration of the most recent depressive episode; duration of current remission; and current level of psychosocial functioning.</p><p>Patients treated for bipolar major depression should also be monitored for symptoms of hypomania and mania. The course of illness is such that depressed patients can spontaneously develop concurrent symptoms of hypomania/mania (mixed features), or switch from depression to hypomania/mania, despite the use of antimanic drugs such as <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a>, second-generation antipsychotics, and <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a>. In addition, some patients may be vulnerable to hypomania/mania induced by antidepressants. (See  <a class="medical medical_review" href="/d/html/14655.html" rel="external">"Bipolar major depression in adults: Efficacy and adverse effects of antidepressants", section on 'Risk of switching to mania'</a>.)</p><p>Measurement based care is the systematic and quantitative assessment of symptoms with rating scales during treatment. Rating scales that can be used to monitor depressive syndromes include the Patient Health Questionnaire – Nine Item (PHQ-9)  (<a class="graphic graphic_table graphicRef59307" href="/d/graphic/59307.html" rel="external">table 4</a>) [<a href="#rid20">20</a>] and the Quick Inventory of Depressive Symptomatology – Self-Report 16 Item (QIDS-SR<sub>16</sub>)  (<a class="graphic graphic_table graphicRef55461" href="/d/graphic/55461.html" rel="external">table 5</a>) [<a href="#rid21">21,22</a>], which are self-report instruments that have good psychometric properties and were developed for use in patients with unipolar major depression. Additional information about these instruments is discussed separately. (See  <a class="medical medical_review" href="/d/html/14860.html" rel="external">"Using scales to monitor symptoms and treat depression (measurement based care)", section on 'Patient Health Questionnaire - Nine Item'</a>.)</p><p>Routine monitoring with rating scales may identify nonresponders, detect residual or prodromal symptoms, and help patients recognize improvement; however, the use of rating scales is not standard clinical practice. There is no evidence demonstrating that measurement based care improves outcomes for bipolar major depression; this may be due in part to the scarce literature.</p><p>For patients who are treated with second-generation antipsychotics, especially <a class="drug drug_general" data-topicid="9570" href="/d/drug information/9570.html" rel="external">quetiapine</a> or <a class="drug drug_general" data-topicid="9716" href="/d/drug information/9716.html" rel="external">olanzapine</a>, we suggest monitoring metabolic parameters  (<a class="graphic graphic_table graphicRef74435" href="/d/graphic/74435.html" rel="external">table 6</a>) to help patients avoid weight gain and the metabolic syndrome. (See  <a class="medical medical_review" href="/d/html/14776.html" rel="external">"Second-generation antipsychotic medications: Pharmacology, administration, and side effects", section on 'Metabolic syndrome'</a>.)</p><p class="headingAnchor" id="H2430837885"><span class="h3">Nonadherence</span><span class="headingEndMark"> — </span>Clinicians should assess patients with bipolar disorder for nonadherence and address it when present [<a href="#rid23">23</a>]. (See  <a class="medical medical_review" href="/d/html/96007.html" rel="external">"Bipolar disorder in adults: Managing poor adherence to maintenance pharmacotherapy"</a>.)</p><p class="headingAnchor" id="H4080527171"><span class="h2">Adjunctive psychotherapy</span><span class="headingEndMark"> — </span>Although the cornerstone of treatment for bipolar major depression is pharmacotherapy, we frequently prescribe adjunctive psychotherapy to:</p><p class="bulletIndent1"><span class="glyph">●</span>Educate patients about the illness, including symptoms, course of illness, treatment options, and sequelae</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Enhance acceptance of the diagnosis and adherence to pharmacotherapy</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ameliorate symptoms</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Address comorbid psychiatric disorders (eg, personality disorders or substance use disorders)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Promote self-management, which includes creating structure and adopting daily routines, being physically active, monitoring symptoms, and avoiding potentially mood destabilizing activities such as alcohol misuse and use of cannabis and other drugs</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Manage stress</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Address problems with relationships and work</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Develop a plan to cope with acute crises</p><p></p><p>Clinicians should educate and support all patients with bipolar major depression, as well as family members, caregivers, and supportive others, when appropriate. Using psychotherapy is consistent with recommendations in multiple treatment guidelines [<a href="#rid9">9,19,23-27</a>] and reviews [<a href="#rid28">28,29</a>]. Nevertheless, not all patients with bipolar major depression need psychotherapy, such as patients without comorbidity who are knowledgeable about bipolar disorder and adhere to treatment [<a href="#rid30">30</a>].</p><p>We often select cognitive-behavioral therapy (CBT) for bipolar major depression because it has been most widely studied, and in our experience is the most widely available. However, the specific choice of psychotherapy depends upon individual patient needs and preferences, as well as availability of services. As an example, patients with prominent dysfunctional thoughts and difficulties performing tasks may benefit from CBT [<a href="#rid31">31</a>], whereas patients with role disputes or role transitions may benefit from interpersonal psychotherapy [<a href="#rid32">32</a>], and patients with families that are characterized by frequent conflicts, high expressed emotion, and problems with communication and problem solving may benefit from family therapy [<a href="#rid33">33,34</a>]. Another reasonable option is group psychoeducation, which is readily comprehended by most patients and relatively easy to implement in most clinical settings.</p><p>Evidence supporting the use of psychotherapy for bipolar major depression includes a one-year randomized trial that compared adjunctive intensive psychotherapy with brief psychoeducation in patients with bipolar I or II major depression (n = 293) [<a href="#rid35">35</a>]. All patients were treated with pharmacotherapy. Patients assigned to intensive psychotherapy received CBT, family therapy, or interpersonal and social rhythm therapy on a weekly or biweekly basis for up to 30 sessions (mean number = 14) over nine months. Brief psychoeducation consisted of three sessions administered over six weeks. Recovery occurred in more patients treated with intensive psychotherapy than psychoeducation (64 versus 52 percent). In addition, functioning improved more with intensive psychotherapy. Study attrition for intensive psychotherapy and psychoeducation was comparable (36 and 31 percent). No statistically significant difference was observed in the rate of recovery among patients treated with CBT, family therapy, or interpersonal and social rhythm therapy.</p><p>Multiple randomized trials specifically support using CBT for bipolar major depression. As an example, a meta-analysis of four randomized trials (n = 305 patients) found that improvement of depressive symptoms was superior with adjunctive CBT than usual care, and the clinical effect was small to moderate [<a href="#rid24">24,36</a>].</p><p>Psychotherapy (eg, group psychoeducation or interpersonal social rhythm therapy) can also be effective for maintenance treatment of bipolar disorder [<a href="#rid37">37</a>]. (See  <a class="medical medical_review" href="/d/html/14666.html" rel="external">"Bipolar disorder in adults: Psychoeducation and other adjunctive maintenance psychotherapies"</a>.)</p><p class="headingAnchor" id="H1608392152"><span class="h2">Comorbidity</span><span class="headingEndMark"> — </span>Bipolar disorder is frequently accompanied by general medical and/or psychiatric comorbidity. (See  <a class="medical medical_review" href="/d/html/14642.html" rel="external">"Bipolar disorder in adults: Clinical features", section on 'Comorbidity'</a>.)</p><p>For patients with bipolar major depression and comorbidity (eg, substance use disorders), we suggest that clinicians attempt to treat both disorders concurrently [<a href="#rid10">10,19,23,38</a>].</p><p class="headingAnchor" id="H2040772786"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/115361.html" rel="external">"Society guideline links: Bipolar disorder"</a>.)</p><p class="headingAnchor" id="H1539321836"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (See  <a class="medical medical_basics" href="/d/html/15348.html" rel="external">"Patient education: Bipolar disorder (The Basics)"</a> and  <a class="medical medical_basics" href="/d/html/16338.html" rel="external">"Patient education: Coping with high drug prices (The Basics)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (See  <a class="medical medical_patient" href="/d/html/4869.html" rel="external">"Patient education: Bipolar disorder (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/16279.html" rel="external">"Patient education: Coping with high prescription drug prices in the United States (Beyond the Basics)"</a>.)</p><p></p><p class="headingAnchor" id="H3530827756"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span>Treatment of acute bipolar depressive episodes begins with a psychiatric and general medical history, mental status and physical examination, and focused laboratory and imaging studies as clinically indicated. (See <a class="local">'Initial assessment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hospitalization may be required for the safety and stabilization of severe bipolar depression, such as patients with suicidal ideation and behavior. Patients with moderate bipolar depression can be treated in a partial hospitalization or intensive outpatient treatment program. Most patients with bipolar depression can be managed in outpatient clinics. (See <a class="local">'Setting'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In selecting pharmacotherapy for patients with bipolar major depression, clinicians should understand that they are likely selecting a maintenance regimen as well. For patients who receive a second-generation antipsychotic as monotherapy, efficacy is often comparable for low doses and high doses, whereas discontinuation of treatment due to adverse effects may occur less often with low doses. (See <a class="local">'Pharmacotherapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The duration of an adequate medication trial for outpatients with bipolar I or II major depression is usually six to eight weeks. However, in clinically urgent situations, if there is minimal improvement within the first few weeks of treatment, it may be acceptable to decide that response is unlikely to occur. (See <a class="local">'Duration of an adequate drug trial'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Clinicians should monitor depressive symptoms, treatment response and adverse effects, and adherence to treatment at each visit. (See <a class="local">'Monitoring'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Although the cornerstone of treatment for bipolar major depression is pharmacotherapy, we often prescribe adjunctive psychotherapy. (See <a class="local">'Adjunctive psychotherapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with bipolar major depression and comorbidity, we suggest that clinicians attempt to treat all of disorders concurrently. (See <a class="local">'Comorbidity'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR), Washington, DC 2022.</li><li><a class="nounderline abstract_t">Judd LL, Akiskal HS, Schettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002; 59:530.</a></li><li><a class="nounderline abstract_t">Judd LL, Akiskal HS, Schettler PJ, et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry 2003; 60:261.</a></li><li><a class="nounderline abstract_t">Simon GE, Bauer MS, Ludman EJ, et al. Mood symptoms, functional impairment, and disability in people with bipolar disorder: specific effects of mania and depression. J Clin Psychiatry 2007; 68:1237.</a></li><li><a class="nounderline abstract_t">Rihmer Z. Prediction and prevention of suicide in bipolar disorders. Clin Neuropsychiatry 2005; 2:48.</a></li><li><a class="nounderline abstract_t">McIntyre RS. Understanding needs, interactions, treatment, and expectations among individuals affected by bipolar disorder or schizophrenia: the UNITE global survey. J Clin Psychiatry 2009; 70 Suppl 3:5.</a></li><li><a class="nounderline abstract_t">Goes FS, Sadler B, Toolan J, et al. Psychotic features in bipolar and unipolar depression. Bipolar Disord 2007; 9:901.</a></li><li><a class="nounderline abstract_t">Hirschfeld RM, Calabrese JR, Frye MA, et al. Defining the clinical course of bipolar disorder: response, remission, relapse, recurrence, and roughening. Psychopharmacol Bull 2007; 40:7.</a></li><li><a class="nounderline abstract_t">Malhi GS, Bassett D, Boyce P, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry 2015; 49:1087.</a></li><li><a class="nounderline abstract_t">Bobo WV. The Diagnosis and Management of Bipolar I and II Disorders: Clinical Practice Update. Mayo Clin Proc 2017; 92:1532.</a></li><li><a class="nounderline abstract_t">Malhi GS, Adams D, Berk M. Medicating mood with maintenance in mind: bipolar depression pharmacotherapy. Bipolar Disord 2009; 11 Suppl 2:55.</a></li><li><a class="nounderline abstract_t">Malhi GS, Bargh DM, McIntyre R, et al. Balanced efficacy, safety, and tolerability recommendations for the clinical management of bipolar disorder. Bipolar Disord 2012; 14 Suppl 2:1.</a></li><li><a class="nounderline abstract_t">Bartoli F, Dell'Osso B, Crocamo C, et al. Benefits and harms of low and high second-generation antipsychotics doses for bipolar depression: A meta-analysis. J Psychiatr Res 2017; 88:38.</a></li><li><a class="nounderline abstract_t">Pacchiarotti I, Mazzarini L, Colom F, et al. Treatment-resistant bipolar depression: towards a new definition. Acta Psychiatr Scand 2009; 120:429.</a></li><li><a class="nounderline abstract_t">Selle V, Schalkwijk S, Vázquez GH, Baldessarini RJ. Treatments for acute bipolar depression: meta-analyses of placebo-controlled, monotherapy trials of anticonvulsants, lithium and antipsychotics. Pharmacopsychiatry 2014; 47:43.</a></li><li><a class="nounderline abstract_t">Sachs GS, Ketter TA. Update on best practices for managing bipolar depression. J Clin Psychiatry 2014; 75:e413.</a></li><li><a class="nounderline abstract_t">Nierenberg AA, McIntyre RS, Sachs GS. Improving outcomes in patients with bipolar depression: a comprehensive review. J Clin Psychiatry 2015; 76:e10.</a></li><li><a class="nounderline abstract_t">Kemp DE, Ganocy SJ, Brecher M, et al. Clinical value of early partial symptomatic improvement in the prediction of response and remission during short-term treatment trials in 3369 subjects with bipolar I or II depression. J Affect Disord 2011; 130:171.</a></li><li><a class="nounderline abstract_t">Goodwin GM, Haddad PM, Ferrier IN, et al. Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2016; 30:495.</a></li><li><a class="nounderline abstract_t">Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001; 16:606.</a></li><li><a class="nounderline abstract_t">Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry 2003; 54:573.</a></li><li><a class="nounderline abstract_t">Trivedi MH, Rush AJ, Ibrahim HM, et al. The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation. Psychol Med 2004; 34:73.</a></li><li><a class="nounderline abstract_t">Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord 2018; 20:97.</a></li><li class="breakAll">National Institute for Health and Care Excellence. Bipolar Disorder: The Assessment and Management of Bipolar Disorder in Adults, Children and Young People in Primary and Secondary Care. National Clinical Guideline Number 185. September, 2014. https://www.nice.org.uk/guidance/cg185/evidence (Accessed on September 14, 2017).</li><li><a class="nounderline abstract_t">Fountoulakis KN, Grunze H, Vieta E, et al. The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 3: The Clinical Guidelines. Int J Neuropsychopharmacol 2017; 20:180.</a></li><li><a class="nounderline abstract_t">Kendall T, Morriss R, Mayo-Wilson E, et al. Assessment and management of bipolar disorder: summary of updated NICE guidance. BMJ 2014; 349:g5673.</a></li><li><a class="nounderline abstract_t">Malhi GS, Bell E, Bassett D, et al. The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry 2021; 55:7.</a></li><li><a class="nounderline abstract_t">Bauer M, Ritter P, Grunze H, Pfennig A. Treatment options for acute depression in bipolar disorder. Bipolar Disord 2012; 14 Suppl 2:37.</a></li><li><a class="nounderline abstract_t">Geddes JR, Miklowitz DJ. Treatment of bipolar disorder. Lancet 2013; 381:1672.</a></li><li class="breakAll">Parker G, Ketter TA. Management of bipolar II disorder. In: Bipolar Disorder: Clinical Foundation, Yatham LN, Maj M (Eds), Wiley-Blackwell, West Sussex, UK 2010. p.342.</li><li class="breakAll">Parikh SV, Scott J. Cognitive-behavioral therapy for bipolar disorder. In: Bipolar Disorder: Clinical and Biological Foundations, Yatham LN, Maj M (Eds), Wiley-Blackwell, West Sussex, United Kingdom 2010. p.422.</li><li class="breakAll">Swartz HA, Frank E, Zajac LE, Kupfer DJ. Interpersonal and social rhythm therapy for bipolar disorder. In: Bipolar Disorder: Clinical and Biological Foundations, Yatham LN, Maj M (Eds), Wiley-Blackwell, West Sussex, United Kingdom 2010. p.430.</li><li class="breakAll">Miklowitz DJ. Family therapy approaches to bipolar disorder. In: Bipolar Disorder: Clinical and Biological Foundations, Yatham LN, Maj M (Eds), Wiley-Blackwell, West Sussex, United Kingdom 2010. p.443.</li><li><a class="nounderline abstract_t">Perlick DA, Jackson C, Grier S, et al. Randomized trial comparing caregiver-only family-focused treatment to standard health education on the 6-month outcome of bipolar disorder. Bipolar Disord 2018; 20:622.</a></li><li><a class="nounderline abstract_t">Miklowitz DJ, Otto MW, Frank E, et al. Psychosocial treatments for bipolar depression: a 1-year randomized trial from the Systematic Treatment Enhancement Program. Arch Gen Psychiatry 2007; 64:419.</a></li><li><a class="nounderline abstract_t">Oud M, Mayo-Wilson E, Braidwood R, et al. Psychological interventions for adults with bipolar disorder: systematic review and meta-analysis. Br J Psychiatry 2016; 208:213.</a></li><li><a class="nounderline abstract_t">Miklowitz DJ, Efthimiou O, Furukawa TA, et al. Adjunctive Psychotherapy for Bipolar Disorder: A Systematic Review and Component Network Meta-analysis. JAMA Psychiatry 2021; 78:141.</a></li><li><a class="nounderline abstract_t">Beaulieu S, Saury S, Sareen J, et al. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid substance use disorders. Ann Clin Psychiatry 2012; 24:38.</a></li></ol></div><div id="topicVersionRevision">Topic 115480 Version 7.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR), Washington, DC 2022.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12044195" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The long-term natural history of the weekly symptomatic status of bipolar I disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12622659" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17854249" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Mood symptoms, functional impairment, and disability in people with bipolar disorder: specific effects of mania and depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Prediction and prevention of suicide in bipolar disorders</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19570496" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Understanding needs, interactions, treatment, and expectations among individuals affected by bipolar disorder or schizophrenia: the UNITE global survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18076541" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Psychotic features in bipolar and unipolar depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18007564" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Defining the clinical course of bipolar disorder: response, remission, relapse, recurrence, and roughening.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26643054" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28888714" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The Diagnosis and Management of Bipolar I and II Disorders: Clinical Practice Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19538686" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Medicating mood with maintenance in mind: bipolar depression pharmacotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22510033" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Balanced efficacy, safety, and tolerability recommendations for the clinical management of bipolar disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28086127" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Benefits and harms of low and high second-generation antipsychotics doses for bipolar depression: A meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19740127" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Treatment-resistant bipolar depression: towards a new definition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24549862" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Treatments for acute bipolar depression: meta-analyses of placebo-controlled, monotherapy trials of anticonvulsants, lithium and antipsychotics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24922493" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Update on best practices for managing bipolar depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25830453" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Improving outcomes in patients with bipolar depression: a comprehensive review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21071096" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Clinical value of early partial symptomatic improvement in the prediction of response and remission during short-term treatment trials in 3369 subjects with bipolar I or II depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26979387" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11556941" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The PHQ-9: validity of a brief depression severity measure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12946886" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14971628" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29536616" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29536616" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27941079" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 3: The Clinical Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25258392" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Assessment and management of bipolar disorder: summary of updated NICE guidance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33353391" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22510035" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Treatment options for acute depression in bipolar disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23663953" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Treatment of bipolar disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23663953" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Treatment of bipolar disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23663953" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Treatment of bipolar disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23663953" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Treatment of bipolar disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23663953" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Treatment of bipolar disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29528180" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Randomized trial comparing caregiver-only family-focused treatment to standard health education on the 6-month outcome of bipolar disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17404119" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Psychosocial treatments for bipolar depression: a 1-year randomized trial from the Systematic Treatment Enhancement Program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26932483" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Psychological interventions for adults with bipolar disorder: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33052390" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Adjunctive Psychotherapy for Bipolar Disorder: A Systematic Review and Component Network Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22303521" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid substance use disorders.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
